Abstract
Abstract Among all new strategies against cancer, the treatments with vaccines, biologics, antibodies, antibody fragments, and other immunological modulators are promising. All of them aim to be more targeted, more effective, and less toxic than other therapies. In order to be developed and accurately evaluated, these immunological related therapies need appropriated preclinical models and relevant immunological readouts. Most of these immunological readouts should be analyzed in vitro, in vivo and ex vivo. A panel of tools from rodents to the bench was evaluated toward the modulation of the immune system by new therapies. All these protocols were developed and validated properly to evaluate these new immunology related cancer therapies. In immunocompetent mice, the immune cells were studied for their cell surface activation markers detection, induction of proliferative phenotype, antigen-specific T lymphocyte detection, secretion of soluble mediators such as cytokines … using FACS phenotyping, cytometric bead assay (CBA) or Luminex multiplex technologies and ELISPOT. In immunodeficient mice, the reconstitution of the mature human immune system with PBMC or naïve human immune system using hematopoietic stem cells were used to evaluate the modulation of those immune cells by therapies through human cytokine release, onset of graft versus host disease. Among other examples, characterization of antibody function (Fab and Fc mediated activities), quantification of the existence and function of antigen-specific T cell clones, phenotyping study of immune cells for activation markers as well as multiplex assays to understand the cytokines network, differentiation of hematopoietic cells by colony formation unit will be described. All of them will be presented in the context either of rodent syngenic model or humanized mouse model. All results, integrative data and examples will be presented in the poster. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5383. doi:1538-7445.AM2012-5383
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
